Ahead of its AGM, disinfectant maker Tristel (TSTL) revealed it had made a strong start to the financial year. The company also said it was ‘firmly on target’ to deliver revenue growth of at least 10% by June 2026.
| Price: 368p +3% | P/E: 30x |
| Market Cap: £175m | Yield: 3.5% |
BIG US SALES BOOST
The AIM-listed firm said it saw strong H1 momentum driven by ‘solid’ UK growth and accelerating demand across Europe. More healthcare providers are adopting its products and its investment in improving its commercial execution is delivering.
Meanwhile, five-month US sales of its ULT ultrasound product are already equivalent to last year’s total sales. In addition, its OHT foam has had an ‘excellent’ start contributing to a five-fold jump in US sales year-to-date.
‘It is pleasing to see increasing demand across Europe, given it is the cornerstone of our international business,’ commented CEO Matt Sassone. ‘In the United States, we are seeing clear evidence of traction and scale-up potential,’ added Sassone.
Tristel shares have been languishing around 350p for several months despite double-digit revenue and earnings growth in FY25. The firm also increased its margins and cash generation, but investors seem to have overlooked it.
Today’s news underpins FY26, especially as H2 tends to have a greater weighting due to winter seasonal demand from hospitals.
Read the press release here: https://investors.tristel.com/
Disclaimer: This content is for information only and is not investment advice. Always do your own research before investing. Click here to see full disclaimer.
